Our goal is to improve the lives of others as much as we can. While our focus is grantmaking, what matters most to us is an organization’s potential for impact — not its tax status.
Good Ventures LLC, at the recommendation of Open Philanthropy, invested in VST Bio to support the development of a novel treatment for stroke and traumatic brain disease.
Good Ventures LLC, at the recommendation of Open Philanthropy, invested in Kainomyx to support the development and production of a new antimalarial drug.
Good Ventures LLC, at the recommendation of Open Philanthropy, invested in Sherlock Biosciences to support the development of a diagnostic platform to identify any human virus present in a patient sample.
Good Ventures LLC, at the recommendation of Open Philanthropy, invested $5 million in EicOsis, a startup developing an oral treatment for neuropathic and inflammatory pain.
Good Ventures LLC, at the recommendation of Open Philanthropy, invested $5.4 million in VasoRX, a startup developing a new therapy for vascular diseases such as atherosclerosis that are among the leading causes of death in the developed world.
In February 2018, Good Ventures LLC invested $14 million in the Dementia Discovery Fund, a venture capital fund investing in novel science to create new medicines for dementia, which affects more than 47 million people worldwide.